PRospective Multiple Myeloma Impact Study (PROMMIS)

We are doing this study to learn if the MMprofiler test can help your doctor in making decisions about your treatment. The MMprofiler genomic test will look at a large number of normal genes. The test will predict risk of your multiple myeloma by assessing whether these genes are turned on or off in your cancer cells. The purpose of this research is to study whether this test can help your doctor to determine what treatment will be best for your multiple myeloma.

As part of your normal medical care, your doctors will take a bone marrow sample. A small piece of this bone marrow sample will be used for the MMprofiler test.

If you agree to participate in this study no additional examinations, blood tests, or x-rays will be performed above and beyond your regular medical care.

Your doctor will be asked to complete a questionnaire about his/her treatment intention for you before he or she receives the MMprofiler result and after he or she receives the MMprofiler result.

The results of MMprofiler and the questionnaires will be stored in a database with additional medical information about you and your multiple myeloma. This includes, but is not limited to, your age, race/ethnicity, other diagnostic tests, your treatment and the response to your treatment. No personal information will be stored in the database, but there will be a code that links your identity to your data. Data will be collected at five (5) different time points:

Before the doctor receives the MMprofiler results
After the doctor receives the MMprofiler results
One (1) year after the MMprofiler test was done
Three (3) years after the MMprofiler test was done
Five (5) years after the MMprofiler test was done

Taking part in this study may or may not make your health better. However, the knowledge gained from this research may benefit future patients with multiple myeloma.

SparkCures ID	920
Trial Phase	Observational Trial
Enrollment	250 Patients
Trial Sponsors	SkylineDx
NCT Identifier	NCT02911571

Are at least 18 years.
Have multiple myeloma according to IMWG criteria.
Are a candidate for systemic treatment.
Additional inclusion/exclusion criteria may apply.

The following criteria is provided for health care professionals.

Patient is at least 18 years old
Patients with Multiple Myeloma according to IMWG criteria or patients highly suspected of having Multiple Myeloma
No more than 8 weeks of first line therapy for Multiple Myeloma

🤔 Am I Eligible?

Understanding this criteria can be difficult - call us today.

(888) 828-2206 Create My Account